Sarcoidosis: Clinical Trials

55 trials for Sarcoidosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

27 completed, 10 terminated, 6 not yet recruiting, 5 withdrawn. 55 Phase 2, 11 Phase 3, 7 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 255Completed 27, Terminated 10, Not yet recruiting 6, Withdrawn 5, Recruiting 4, Unknown 2, Active not recruiting 1
Phase 311Completed 6, Unknown 2, Not yet recruiting 1, Recruiting 1, Terminated 1
Phase 17Completed 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1

Follow Sarcoidosis: new trials by email Literature Review of Sarcoidosis trials Research Report on Sarcoidosis

Trials (filtered) newest first · largest first

All 55 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH)
Placebo, LAM-001 - Sarcoidosis Associated Pulmonary Hypertension
Phase 2Not yet recruitingIRulya Therapeutics Inc.602026-12-012026-10-21
A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)
Tulisokibart, Placebo, Background prednisone therapy - Pulmonary Sarcoidosis
Phase 2RecruitingMerck Sharp & Dohme LLC1582026-11-032026-11-09
Evaluation of the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis
Prednisone, Compound betamethasone - Sarcoidosis, Pulmonary
Phase 2 / Phase 3Not yet recruitingPeking Union Medical College Hospital1262026-11-012026-10-15
An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
XTMAB-16, Placebo - Pulmonary Sarcoidosis
Phase 2Not yet recruitingXentria, Inc.1822026-10-302026-10-21
FAPI PET Imaging - An Exploratory Study
[18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N)
Phase 1 / Phase 2Not yet recruitingMartin Huellner7702026-08-012026-07-15
A Trial of Baricitinib in Patients With Cardiac Sarcoidosis
Baricitinib (LY3009104) 4 mg - Cardiac Sarcoidosis
Phase 2Not yet recruitingStanford University102026-04-012026-02-10
Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis
Metformin, Cellulose - Sarcoidosis, Pulmonary
Phase 2WithdrawnUniversity of Maryland, Baltimore2025-12-102025-02-11
A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis
Oral Brepocitinib, Oral Placebo - Cutaneous Sarcoidosis
Phase 2 / Phase 3RecruitingPriovant Therapeutics, Inc.1682025-04-092026-11-03
Tyrosine Kinase 2 (TYK2) for GA and CS
Deucravacitinib - Sarcoidosis, Granuloma Annulare
Phase 2WithdrawnYale University2025-03-012025-04-29
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
OATD-01, Placebo - Pulmonary Sarcoidosis
Phase 2RecruitingMolecure S.A.962024-03-212026-10-08
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
XTMAB-16 - Pulmonary Sarcoidosis
Phase 2CompletedXentria, Inc.312024-03-012026-10-16
Feasibility of Semaglutide in Advanced Lung Disease
Semaglutide Pen Injector - Obesity, Interstitial Lung Disease
Phase 1 / Phase 2RecruitingUniversity of Pennsylvania82024-01-292026-04-21
Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
XTMAB-16 or Placebo - Pulmonary Sarcoidosis
Phase 1 / Phase 2Active not recruitingXentria, Inc.322023-11-102026-10-02
Janus Kinase Inhibition in Sarcoidosis
Abrocitinib 200 mg - Sarcoidosis
Phase 2CompletedYale University102023-06-012026-09-21
A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis
Namilumab, Placebo - Sarcoidosis, Pulmonary
Phase 2TerminatedKinevant Sciences GmbH1072022-08-312025-09-12
A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis
Namilumab - Sarcoidosis, Cardiac
Phase 2TerminatedKinevant Sciences GmbH12022-08-232025-04-17
Sirolimus in Cutaneous Sarcoidosis
Sirolimus - Sarcoidosis, Cutaneous Sarcoidosis
Phase 2Not yet recruitingAssistance Publique - Hôpitaux de Paris102022-07-012022-07-14
A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag
Selexipag, Placebo - Sarcoidosis-associated Pulmonary Hypertension
Phase 2TerminatedActelion102021-02-262024-05-08
Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis
68GaNOTA-Anti-MMR-VHH2 - Solid Malignancy Located in the Head and Neck, Cancer
Phase 2TerminatedUniversitair Ziekenhuis Brussel292021-01-262026-06-01
Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
CMK389, Placebo - Pulmonary Sarcoidosis
Phase 2CompletedNovartis Pharmaceuticals622020-09-232025-04-13

Showing 20 of 55. Sign in to see all of them.

Narrower conditions

Sarcoidosis, Pulmonary (20)  ·  Hypertension, Pulmonary (7)  ·  Lung Diseases, Interstitial (5)  ·  Pulmonary Fibrosis (3)  ·  Granuloma (2)  ·  Inflammation (2)  ·  Lung Diseases (2)  ·  Pulmonary Arterial Hypertension (2)  ·  Autoimmune Diseases (1)  ·  Behcet Syndrome (1)  ·  Birdshot Chorioretinopathy (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Transitional Cell (1)

Broader conditions

Hemic and Lymphatic Diseases (55)  ·  Hypersensitivity (55)  ·  Hypersensitivity, Delayed (55)  ·  Immune System Diseases (55)  ·  Lymphatic Diseases (55)  ·  Lymphoproliferative Disorders (54)  ·  Respiratory Tract Diseases (29)  ·  Lung Diseases (27)  ·  Lung Diseases, Interstitial (20)  ·  Pathological Conditions, Signs and Symptoms (11)  ·  Cardiovascular Diseases (10)  ·  Vascular Diseases (10)  ·  Pathologic Processes (8)  ·  Hypertension (7)

Interventions

Adalimumab (4)  ·  Azithromycin (3)  ·  Bosentan (2)  ·  Ethambutol (2)  ·  Levofloxacin (2)  ·  Prednisone (2)  ·  Rifampin (2)  ·  namilumab (2)  ·  68Ga-DOTANOC (1)  ·  Abatacept (1)  ·  Adrenocorticotropic Hormone (1)  ·  Atorvastatin (1)  ·  Cellulose (1)  ·  Cyclophosphamide (1)  ·  Dapsone (1)

Sponsors

University of Cincinnati (4)  ·  National Heart, Lung, and Blood Institute (NHLBI) (3)  ·  Novartis Pharmaceuticals (3)  ·  Xentria, Inc. (3)  ·  Albany Medical College (2)  ·  Kinevant Sciences GmbH (2)  ·  Post Graduate Institute of Medical Education and Research, Chandigarh (2)  ·  Stanford University (2)  ·  University of Chicago (2)  ·  Vanderbilt University (2)  ·  Yale University (2)  ·  Actelion (1)  ·  Araim Pharmaceuticals, Inc. (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Bellerophon (1)

Countries

United States (42)  ·  United Kingdom (9)  ·  Germany (8)  ·  Netherlands (6)  ·  Belgium (4)  ·  Denmark (4)  ·  France (4)  ·  Czechia (3)  ·  Poland (3)  ·  India (2)  ·  Norway (2)  ·  Spain (2)  ·  Australia (1)  ·  Austria (1)  ·  Brazil (1)

Top investigators

Marc A Judson, MD (3)  ·  Robert P Baughman, MD (3)  ·  Ali Ataya, MD (1)  ·  Daniel Doberer, MD, MSc (1)  ·  Dariusz Stencel, MD (1)  ·  Don C Rockey, MD (1)  ·  Edward Parsley, DO (1)  ·  Gennyne Walker (1)  ·  Joseph Jorizzo, MD (1)  ·  Joseph R Fontana, M.D. (1)  ·  Juhani Knuuti, MD, PhD (1)  ·  Matthew Baker, MD (1)  ·  Matthew C Baker, MD, MS (1)

Results publications

PMID 20926833, PMID 22004880, PMID 23863960, PMID 24177203, PMID 24488568, PMID 24751453, PMID 25034562, PMID 25428650, PMID 25594886, PMID 25638011, PMID 25811287, PMID 33089005, PMID 34029565, PMID 36356657, PMID 37471590, PMID 37854715, PMID 41819539

NIH funding

2009 (1), 2014 (1), 2018 (1), 2023 (1), 2025 (1), R01HL117074 (1)